Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64 Cu-SarAr immunoconjugates

Thumbnail Image

Date

2007

Authors

Voss, Stephan D
Smith, Suzanne
DiBartolo, Nadine
McIntosh, Lacey J
Cyr, Erika M
Bonab, Ali A
Dearling, Jason L J
Carter, Edward A
Fischman, Alan J
Treves, S Ted

Journal Title

Journal ISSN

Volume Title

Publisher

National Academy of Sciences (USA)

Abstract

The advancement of positron emission tomography (PET) depends on the development of new radiotracers that will complement 18F-FDG. Copper-64 (64Cu) is a promising PET radionuclide, particularly for antibody-targeted imaging, but the high in vivo lability

Description

Keywords

Keywords: 1 n (4 aminobenzyl) 3,6,10,13,16,19 hexaazabicyclo[6 6 6]eicosane 1,8 diamine; antibody conjugate; chelating agent; copper 64; ganglioside GD2; radiopharmaceutical agent; unclassified drug; animal experiment; animal model; article; controlled study; human

Citation

URI

http://hdl.handle.net/1885/38882

Collections

ANU Research Publications

Source

PNAS - Proceedings of the National Academy of Sciences of the United States of America

Type

Journal article

Book Title

Entity type

Access Statement

License Rights

DOI

10.1073/pnas.0708436104

Restricted until

2037-12-31

Downloads

File
Description
01_Voss_Positron_emission_tomography_2007.pdf (415.63 KB)

DSpace software copyright © 2002-2026 LYRASIS